More than 75% of non-small cell lung cancer (NSCLC) patients have multiple subclonal driver mutations, which affect the response of high-grade lung cancer to EGFR treatment (Blakely et al., 2017; Jamal-Hanjani et al., 2017). This evidence concerns the gene EGFR and lung carcinoma.